TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Recruiting · NCT06589830 · Registry updated 2026-04-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-04-28 | NCT06589830 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Suzhou Teligene Ltd. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer hospital, Chinese Academy of Medical Sciences | Beijing | China | 12 |